Morningside Pharmaceuticals add Mawdsleys as a distributor to Hospitals
Morningside Pharmaceuticals add Mawdsleys as a distributor to Hospitals 4th March 2021

Mawdsleys is delighted to now be partnering with Morningside Pharmaceuticals as an additional distributor to supply their contract and non-contract products to hospitals.

 

Morningside has a portfolio of 242 generic and branded licensed medicines in the UK and EU and is a proud manufacturer and supplier to NHS Trusts, pharmacy chains, pharmaceutical wholesalers, as well as clinics and dispensing doctors in the UK.

Morningside’s products are available for customers to order now from Mawdsleys.

Other latest news
https://www.mawdsleys.co.uk/news/mawdsleys-at-clinical-pharmacy-congress-2024/ thumbnail image Clinical Pharmacy Congress 2024

We recently exhibited at Clinical Pharmacy Congress at ExCel London. We were there to showcase how we innovate the world of pharma supply and distribution with:   Hospital Distribution Imported Unlicensed Medicines  Hospital Over-labelling  Healthcare Third Party Logistics   It was a very productive show and we had some great…

Read more
https://www.mawdsleys.co.uk/news/mawdsleys-and-meabco-launch-a-named-patient-supply-program-for-bp-c1/ thumbnail image Mawdsleys and Meabco launch a Named Patient Supply program for BP-C1

Mawdsleys and Meabco A/S have launched a Named Patient Supply program to allow Oncologists within the European Union (EU) to obtain access to BP-C1 on an unlicensed basis for the treatment of metastatic breast cancer and incurable pancreatic cancer.   BP-C1 is a new benzene-poly-carboxylic acids complex with cis-diammineplatinum (II)…

Read more